Picture of Nyxoah SA logo

NYXH — Nyxoah SA News Story

0.000.00%
be flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Belgium's Nyxoah falls on delayed launch of sleep apnea device

** U.S.-listed shares of Belgian medical device maker Nyxoah NYXH.BR, NYXH.O fall ~15% to $9.63

** Co says U.S. FDA has issued an "Approvable Letter" for Genio system to treat moderate to severe sleep apnea

** Obstructive sleep apnea patients stop breathing briefly while sleeping

** FDA issues approvable letters when it classifies a device as approved, pending information such as review of manufacturing

** Piper Sandler analyst Adam Maeder says the update "derisks" U.S. regulatory approval process

** Says approval and launch expected to be delayed by about 1-2 quarters, but revenue impact to be "negligible in the bigger picture"

** Co was expecting approval by the end of 1Q25

** NYXH fell 16.4% in the last 12 months

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))

Recent news on Nyxoah SA

See all news